Statins are active in acute lymphoblastic leukaemia (ALL): A therapy that may treat ALL and prevent avascular necrosis

British Journal of Haematology

Volumn 155, Issue 3, 2011, Pages 403-407

  Sheen, Cecilia ^a   Vincent, Tiffaney ^a   Barrett, David ^a   Horwitz, Edwin M ^a   Hulitt, Jessica ^a   Strong, Eliza ^a   Grupp, Stephan A ^a   Teachey, David T ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Late effects of therapy; Lipid mediators; New drugs for leukaemia

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ATORVASTATIN; COMPACTIN; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVALONOLACTONE; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PRAVASTATIN; RAF PROTEIN; SIMVASTATIN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AVASCULAR NECROSIS; CANCER CELL CULTURE; CELL ASSAY; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; HYDROPHILICITY; LETTER; LIPOPHILICITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

CELL GROWTH PROCESSES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OSTEONECROSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS;

EID: 80053953651     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08696.x     Document Type: Letter

References (10)

1. Burke, L.P. & Kukoly, C.A. (2008) Statins induce lethal effects in acute myeloblastic lymphoma cells within 72hours. Leukaemia & Lymphoma, 49, 322-330.
2. Gbelcova, H., Lenicek, M., Zelenka, J., Knejzlik, Z., Dvorakova, G., Zadinova, M., Pouckova, P., Kudla, M., Balaz, P., Ruml, T. & Vitek, L. (2008) Differences in antitumor effects of various statins on human pancreatic cancer. International Journal of Cancer, 122, 1214-1221.
3. Iwakiri, K., Oda, Y., Kaneshiro, Y., Iwaki, H., Masada, T., Kobayashi, A., Asada, A. & Takaoka, K. (2008) Effect of simvastatin on steroid-induced osteonecrosis evidenced by the serum lipid level and hepatic cytochrome P4503A in a rabbit model. Journal of Orthopaedic Science, 13, 463-468.
4. Kawedia, J.D., Kaste, S.C., Pei, D., Panetta, J.C., Cai, X., Cheng, C., Neale, G., Howard, S.C., Evans, W.E., Pui, C.H. & Relling, M.V. (2011) Pharmacokinetic, pharmacodynamic and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood, 117, 2340-2347.
5. Neuhaus, O., Strasser-Fuchs, S., Fazekas, F., Kieseier, B.C., Niederwieser, G., Hartung, H.P. & Archelos, J.J. (2002) Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology, 59, 990-997.
6. Rambal, A.A., Panaguiton, Z.L., Kramer, L., Grant, S. & Harada, H. (2009) MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM. Leukemia, 23, 1744-1754.
7. Sala, A., Mattano, Jr, L.A. & Barr, R.D. (2007) Osteonecrosis in children and adolescents with cancer - an adverse effect of systemic therapy. European Journal of Cancer, 43, 683-689.
8. Teachey, D.T., Obzut, D.A., Cooperman, J., Fang, J., Carroll, M., Choi, J.K., Houghton, P.J., Brown, V.I. & Grupp, S.A. (2006) The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood, 107, 1149-1155.
9. Teachey, D.T., Sheen, C., Hall, J., Ryan, T., Brown, V.I., Fish, J., Reid, G.S., Seif, A.E., Norris, R., Chang, Y.J., Carroll, M. & Grupp, S.A. (2008) mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood, 112, 2020-2023.
10. Wu, J., Wong, W.W., Khosravi, F., Minden, M.D. & Penn, L.Z. (2004) Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Research, 64, 6461-6468.